Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Waleed Abdelall, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Keyur P. Patel, MD PhD, Elias J. Jabbour, MD, Naval G. Daver, MD, Tapan Kadia, MD, Rosilyn A. Gborogen, RN, Marina Konopleva, MD PhD, Farhad Ravandi, MD, Michael Andreef, MD PhD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1642.

https://doi.org/10.1182/blood.V128.22.1642.1642

Published: 2016

Journal Articles

Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis

Abdallah Abou Zahr, Jorge E. Cortes, MD, Srdan Verstovsek, MD PhD, Jairo Matthews, Nitin Jain, MD, Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Michael Andreef, MD PhD, Kiran Naqvi, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2016) 128 (22): 3062.

https://doi.org/10.1182/blood.V128.22.3062.3062

Published: 2016

Journal Articles

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Blood (2015) 126 (23): 258.

https://doi.org/10.1182/blood.V126.23.258.258

Published: 2015

Journal Articles

Mixed Phenotype Acute Leukemia (MPAL) Has a High Frequency of Mutations in Epigenetic Regulatory Genes: Results from Whole Exome Sequencing

Olive S. Eckstein, MD, Linghua Wang, MD PhD, Jyotinder N. Punia, MD, Steven M. Kornblau, MD, Michael Andreef, MD PhD, David A. Wheeler, PhD, Margaret A. Goodell, PhD

Blood (2014) 124 (21): 3560.

https://doi.org/10.1182/blood.V124.21.3560.3560

Published: 2014

Journal Articles

Prognostic Impact and Targeting of BMI-1 in Acute Myeloid Leukemia

Yuki Nishida, MD, Kensuke Kojima, MD PhD, Aya Maeda, Dhruv Chachad, MS, Hiroaki Kitamura, MD, Jo Ishizawa, MD PhD, Michael Andreef, MD PhD, Steven M. Kornblau, MD, Shinya Kimura, MD

Blood (2014) 124 (21): 3617.

https://doi.org/10.1182/blood.V124.21.3617.3617

Published: 2014

Journal Articles

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Jasleen K. Randhawa, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Philip Alastair Thompson, MBBS,FRCPA,FRACP, Maria Konopleva, MD PhD, Naval Daver, MD, Naveen Pemmaraju, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Zeev Estrov, MD, Abhijit Ramachandran, PhD, Jamil Paradela, Michael Andreef, MD PhD, Mark Levis, MD PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 389.

https://doi.org/10.1182/blood.V124.21.389.389

Published: 2014

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),

Jorge E. Cortes, Guillermo Garcia-Manero, Farhad Ravandi, MBBS, Michael Andreef, MD, PhD, Gautam Borthakur, Elias Jabbour, Marina Konopleva, M.D., Ph.D., Susan o'Brien, Alfonso Quintas-Cardama, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3639.

https://doi.org/10.1182/blood.V118.21.3639.3639

Published: 2011

Journal Articles

The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction

Adam Jona, Noor Khaskhely, MD, PhD, Daniela Buglio, MD, PhD, Jessica A. Shafer, MD, Enrico Derenzini, MD, Catherine M Bollard, MD, Arpad Illes, MD, PhD, Michael Andreef, MD, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2850.

https://doi.org/10.1182/blood.V116.21.2850.2850

Published: 2010

Journal Articles

Immunotherapy of Chronic Lymphocytic Leukemia using CD40L and IL2 Expressing Autologous Tumor Cells.

Ettore Biagi, MD, Uday Popat, MD, Rousseau Raphael, MD, Yvon Eric, MS, Dotti Giampietro, MD, Rice Lawrence, MD, Michael Andreef, MD, PhD, Malcolm Brenner, MD, PhD

Blood (2004) 104 (11): 768.

https://doi.org/10.1182/blood.V104.11.768.768

Published: 2004

NARROW

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Mixed Phenotype Acute Leukemia (MPAL) Has a High Frequency of Mutations in Epigenetic Regulatory Genes: Results from Whole Exome Sequencing

Prognostic Impact and Targeting of BMI-1 in Acute Myeloid Leukemia

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),

The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction

Immunotherapy of Chronic Lymphocytic Leukemia using CD40L and IL2 Expressing Autologous Tumor Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only